Scale-up and deliver allogeneic cell therapies to large patient populations

Marcos Langtry is Head of Allogeneic Cell Therapy Commercial Development at Lonza Pharma & Biotech. He is responsible for the allogeneic commercial strategy, current and future offerings, and portfolio optimization. Before joining Lonza, Marcos held several senior level positions at TiGenix, Astra Zeneca and Sanofi in the areas of external manufacturing, process development, technical operations and industrial strategy; where he acquired extensive experience with aseptically filled, biologic and cell therapy products.

Marcos Langtry holds a Master´s degree in Biochemical Engineering from University College London (UK) and an MBA from Imperial College London (UK). He is also qualified as Chartered Engineer (CEng) and Chartered Scientist (CSci).

Dr. Panchalingam is a Senior Scientist in the Cell and Gene Therapy Process Development group, Emerging Technologies at Lonza. He has over 14 years of experience in stem cell bioengineering, bioprocessing and in the cell and gene therapy field. Dr. Panchalingam holds a PhD degree in Chemical Engineering from the University of Calgary (Calgary, Canada) where he focused on the development of viable, scalable, and defined bioprocesses in the field of regenerative medicine.

After completing his PhD, Dr. Panchalingam started as a Bioprocess Scientist/Engineer at CCRM (Toronto, Canada), leading the development and optimization of large-scale immune cell and iPSC-based manufacturing processes and the controlled differentiation of iPSCs to cardiomyocytes.

Since joining Lonza in 2016, Dr. Panchalingam has been leading the development of new technologies and robust manufacturing processes for the clinical manufacturing of next generation cell and gene therapies.

Dr. Inbar Friedrich Ben-Nun is a Sr. Manager in the Cell and Gene Therapy R&D at Lonza. Inbar obtained her PhD in Molecular and Structural Biochemistry at the Hebrew University of Jerusalem. As a postdoctoral fellow at the Scripps Research Institute, CA, she acquired extensive experience with pluripotent stem cells. Her work published in “Nature Methods” showed for the first time that stem cell research could be apply to save species from extinction.

Inbar has joined Lonza in 2011, and in her current role she leads a team that focuses on developing innovative solutions to enable stem cell-based therapies.